← Leaderboards
Jeffrey S Glenn
Stanford University
$57,102,148
Attributed
$57,304,090
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $94M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$154,983,742 · 17
By mechanism
U19$133,239,763 · 8
R01$19,707,106 · 6
R56$1,332,988 · 1
R43$403,885 · 1
R41$300,000 · 1
Top collaborators
- Maria T Millan2 shared
Most similar at Stanford University
Same institution · by research overlap
- George F Van Hare$1,452,203
- Bali Pulendran$71,035,530
- Dale T Umetsu$13,091,949
- Rosemarie Dekruyff$4,713,762
Others in their field
Top investigators on “Antiviral Agents”
- Constance Ann Benson · University Of California, San Diego$209,152,068
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$120,325,769
- Judith S. Currier · University Of California Los Angeles$102,391,456
- Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
- Sharon A Nachman · Johns Hopkins University$77,262,665
- John Damon Chodera · Sloan-Kettering Inst Can Research$58,660,403
Research focus
Antiviral AgentsVirusBaseLeadResistanceCellsViralToxic EffectIn VitroInhibitor/AntagonistPathogenSmall MoleculeClinicMediatingHepatitis C VirusPharmaceutical PreparationsRna VirusesGenomeProteinsMutationIn VivoPhosphotransferasesInterferonsPhosphatidylinositols
Grant awards (60)
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm$746,350
R01 · FY2025 · AI · contact PI
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm$752,485
R01 · FY2024 · AI · contact PI
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm$758,444
R01 · FY2023 · AI · contact PI
Development of outpatient antiviral cocktails against SARS-CoV-2 and other potential pandemic RNA viruses.$69,058,677
U19 · FY2022 · AI · contact PI
Oral small molecule inhibitors of NSP4-mediated membrane-associated RNA replication of SARS-CoV-2 and other RNA viruses$9,266,568
U19 · FY2022 · AI · contact PI
Programmable antivirals: Targeting viral RNA secondary structures with LNAs and small molecules$8,915,196
U19 · FY2022 · AI · contact PI
Administrative Core$5,996,064
U19 · FY2022 · AI · contact PI
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm$772,053
R01 · FY2022 · AI · contact PI
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm$799,024
R01 · FY2021 · AI · contact PI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND$1,112,974
R01 · FY2020 · AI · contact PI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND$745,482
R01 · FY2020 · AI · contact PI
Rapid development of SARS-CoV-2 specific therapeutics that leverage virus specific RNA elements$348,164
R01 · FY2020 · AI · contact PI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND$1,121,874
R01 · FY2019 · AI · contact PI
Advancing Broad Spectrum Host-Targeting Antiviral Strategies to the Clinic$329,066
U19 · FY2019 · AI · contact PI
Advancing Broad Spectrum Host-Targeting Antiviral Strategies to the Clinic$5,480,207
U19 · FY2018 · AI · contact PI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND$1,489,636
R01 · FY2018 · AI · contact PI
PK-enhanced PI-Kinase (PI4K; PI5K) Inhibitors of RNA Viruses$1,341,829
U19 · FY2018 · AI · contact PI
Haploid genetic screen to identify host genes required for RNA virruses$448,661
U19 · FY2018 · AI · contact PI
Administrative Core$220,762
U19 · FY2018 · AI · contact PI
Advancing Broad Spectrum Host-Targeting Antiviral Strategies to the Clinic$6,032,754
U19 · FY2017 · AI · contact PI
PK-enhanced PI-Kinase (PI4K; PI5K) Inhibitors of RNA Viruses$1,332,839
U19 · FY2017 · AI · contact PI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND$1,000,000
R01 · FY2017 · AI · contact PI
Administrative Core$790,842
U19 · FY2017 · AI · contact PI
Haploid genetic screen to identify host genes required for RNA virruses$449,319
U19 · FY2017 · AI · contact PI
Advancing Broad Spectrum Host-Targeting Antiviral Strategies to the Clinic$6,002,828
U19 · FY2016 · AI · contact PI
PK-enhanced PI-Kinase (PI4K; PI5K) Inhibitors of RNA Viruses$1,468,743
U19 · FY2016 · AI · contact PI
The PIP2-virus interface and PI 4-kinase: novel biology and validation targets$996,649
R01 · FY2016 · AI · contact PI
Administrative Core$738,332
U19 · FY2016 · AI · contact PI
Haploid genetic screen to identify host genes required for RNA virruses$424,601
U19 · FY2016 · AI · contact PI
Advancing Broad Spectrum Host-Targeting Antiviral Strategies to the Clinic$5,471,076
U19 · FY2015 · AI · contact PI
PK-enhanced PI-Kinase (PI4K; PI5K) Inhibitors of RNA Viruses$1,490,058
U19 · FY2015 · AI · contact PI
The PIP2-virus interface and PI 4-kinase: novel biology and validation targets$1,027,579
R01 · FY2015 · AI · contact PI
Haploid genetic screen to identify host genes required for RNA virruses$424,660
U19 · FY2015 · AI · contact PI
Administrative Core$209,983
U19 · FY2015 · AI · contact PI
Advancing Broad Spectrum Host-Targeting Antiviral Strategies to the Clinic$5,305,044
U19 · FY2014 · AI · contact PI
PK-enhanced PI-Kinase (PI4K; PI5K) Inhibitors of RNA Viruses$1,425,487
U19 · FY2014 · AI · contact PI
Advancing a Novel Pangenotypic Inhibitor of Human Influenza Virus to an IND$1,332,988
R56 · FY2014 · AI · contact PI
The PIP2-virus interface and PI 4-kinase: novel biology and validation targets$1,057,049
R01 · FY2014 · AI · contact PI
Haploid genetic screen to identify host genes required for RNA virruses$412,296
U19 · FY2014 · AI · contact PI
HCV NS4B: Translating molecular virology into novel antiviral therapies$396,363
R01 · FY2014 · AI · contact PI
Administrative Core$203,871
U19 · FY2014 · AI · contact PI
The PIP2-virus interface and PI 4-kinase: novel biology and validation targets$1,020,814
R01 · FY2013 · AI · contact PI
HCV NS4B: Translating molecular virology into novel antiviral therapies$372,581
R01 · FY2013 · AI · contact PI
The PIP2-virus interface and PI 4-kinase: novel biology and validation targets$1,127,800
R01 · FY2012 · AI · contact PI
HCV NS4B: Translating molecular virology into novel antiviral therapies$396,363
R01 · FY2012 · AI · contact PI
HCV NS4B: Translating molecular virology into novel antiviral therapies$416,837
R01 · FY2011 · AI · contact PI
HCV NS4B: Translating molecular virology into novel antiviral therapies$437,035
R01 · FY2010 · AI · contact PI
Advancing clemizole for hepatitis C: towards a pre-IND package$300,000
R41 · FY2010 · AI · contact PI
HCV NS5A: Molecular Virology and Antiviral Target$100,000
R01 · FY2010 · DK · contact PI
Towards the creation of HCV-resistant liver cells for transplantation$98,685
R43 · FY2010 · DK
Towards the creation of HCV-resistant liver cells for transplantation$305,200
R43 · FY2008 · DK
HCV NS5A: Molecular Virology and Antiviral Target$261,667
R01 · FY2008 · DK · contact PI
Novel Antiviral Targets in Hepatitis C virus NS4B$326,176
R01 · FY2007 · DK · contact PI
HCV NS5A: Molecular Virology and Antiviral Target$267,008
R01 · FY2007 · DK · contact PI
Novel Antiviral Targets in Hepatitis C virus NS4B$335,917
R01 · FY2006 · DK · contact PI
HCV NS5A: Molecular Virology and Antiviral Target$274,982
R01 · FY2006 · DK · contact PI
Novel Antiviral Targets in Hepatitis C virus NS4B$344,000
R01 · FY2005 · DK
HCV NS5A: Molecular Virology and Antiviral Target$278,900
R01 · FY2005 · DK
Novel Antiviral Targets in Hepatitis C virus NS4B$344,000
R01 · FY2004 · DK
HCV NS5A: Molecular Virology and Antiviral Target$278,900
R01 · FY2004 · DK